Clinical characteristics of 30 patients with acute myeloid leukemia
| Patient . | Expression ofMDR1 gene polymorphism (G/T variant) . | Diagnosis . | Relapse/Refractory disese . | ||||
|---|---|---|---|---|---|---|---|
| Age (years) . | FAB classification . | Karyotype . | Relapse free after 1st CR (months) . | Treatment (at time of relapse/ refractory disease) . | Response (to reinduction) . | ||
| 1 | GT | 2 | M5 | Unfavorable | 8 | NT | |
| 2 | G | 1 | M6 | Neutral | 4 | 2cdA/Ara-C/Idarubicin | No CR |
| 3 | GT | 47 | M2 | Neutral | 50 | HOVON30 | CR |
| 4 | T | 55 | M2 | Neutral | — | HOVON30 | No CR** |
| 5 | T | 50 | M5 | Neutral | 25 | HOVON30 | CR |
| 6 | GT | 50 | M2 | Neutral | 7 | HOVON30 | CR |
| 7 | GT | 62 | M1 | Unfavorable | 31 | HOVON30 | CR |
| 8 | GT | 61 | M1 | Neutral | 29 | HOVON30 | No CR |
| 9 | GT | 35 | M1 | Favorable | 12 | HOVON30 | CR |
| 10 | GT | 9 | M5 | Unfavorable | 9 | NT | |
| 11 | GT | 12 | M1 | Neutral | 33 | DCLSG ANLL94 | CR |
| 12 | GT | 37 | M1 | Neutral | 12 | HOVON29 | CR |
| 13 | GT | 57 | M4 | Neutral | 4 | NT | |
| 14 | G | 46 | M5a | Neutral | 6 | NT | |
| 15 | GT | 67 | M2 | Neutral | 9 | EORTC 9 | No CR |
| 16 | T | 16 | M4eo | Favorable | 8 | HOVON29 | CR |
| 17 | GT | 19 | M5a | Neutral | 28 | HOVON29 | No CR |
| 18 | GT | 42 | M2 | Neutral | 11 | HOVON29 | CR |
| 19 | GT | 1 | M1 | Neutral | 14 | DCLSG ANLL87 | No CR |
| 20 | G | 41 | M6 | Neutral | 4 | HOVON30 | CR |
| 21 | GT | 10 | M2 | Favorable | 58 | DCLSG ANLL94 | CR |
| 22 | T | 63 | M2 | Neutral | 20 | NT | |
| 23 | G | 1 | M5 | Unfavorable | 10 | DCLSG ANLL87 | No CR |
| 24 | GT | 27 | M2 | Neutral | 14 | HOVON30 | CR |
| 25 | G | 34 | M5 | Neutral | — | HOVON30 | No CR** |
| 26 | GT | 5 | M1 | Neutral | 18 | DCLSG ANLL87 | CR |
| 27 | G | 18 | M2 | Neutral | 8 | Mitoxantrone | No CR |
| 28 | T | 55 | M1 | Neutral | — | HOVON30 | No CR** |
| 29 | T | 49 | M2 | Neutral | 6 | NT | |
| 30 | G | 67 | M2 | Neutral | 5 | HOVON30 | No CR |
| Patient . | Expression ofMDR1 gene polymorphism (G/T variant) . | Diagnosis . | Relapse/Refractory disese . | ||||
|---|---|---|---|---|---|---|---|
| Age (years) . | FAB classification . | Karyotype . | Relapse free after 1st CR (months) . | Treatment (at time of relapse/ refractory disease) . | Response (to reinduction) . | ||
| 1 | GT | 2 | M5 | Unfavorable | 8 | NT | |
| 2 | G | 1 | M6 | Neutral | 4 | 2cdA/Ara-C/Idarubicin | No CR |
| 3 | GT | 47 | M2 | Neutral | 50 | HOVON30 | CR |
| 4 | T | 55 | M2 | Neutral | — | HOVON30 | No CR** |
| 5 | T | 50 | M5 | Neutral | 25 | HOVON30 | CR |
| 6 | GT | 50 | M2 | Neutral | 7 | HOVON30 | CR |
| 7 | GT | 62 | M1 | Unfavorable | 31 | HOVON30 | CR |
| 8 | GT | 61 | M1 | Neutral | 29 | HOVON30 | No CR |
| 9 | GT | 35 | M1 | Favorable | 12 | HOVON30 | CR |
| 10 | GT | 9 | M5 | Unfavorable | 9 | NT | |
| 11 | GT | 12 | M1 | Neutral | 33 | DCLSG ANLL94 | CR |
| 12 | GT | 37 | M1 | Neutral | 12 | HOVON29 | CR |
| 13 | GT | 57 | M4 | Neutral | 4 | NT | |
| 14 | G | 46 | M5a | Neutral | 6 | NT | |
| 15 | GT | 67 | M2 | Neutral | 9 | EORTC 9 | No CR |
| 16 | T | 16 | M4eo | Favorable | 8 | HOVON29 | CR |
| 17 | GT | 19 | M5a | Neutral | 28 | HOVON29 | No CR |
| 18 | GT | 42 | M2 | Neutral | 11 | HOVON29 | CR |
| 19 | GT | 1 | M1 | Neutral | 14 | DCLSG ANLL87 | No CR |
| 20 | G | 41 | M6 | Neutral | 4 | HOVON30 | CR |
| 21 | GT | 10 | M2 | Favorable | 58 | DCLSG ANLL94 | CR |
| 22 | T | 63 | M2 | Neutral | 20 | NT | |
| 23 | G | 1 | M5 | Unfavorable | 10 | DCLSG ANLL87 | No CR |
| 24 | GT | 27 | M2 | Neutral | 14 | HOVON30 | CR |
| 25 | G | 34 | M5 | Neutral | — | HOVON30 | No CR** |
| 26 | GT | 5 | M1 | Neutral | 18 | DCLSG ANLL87 | CR |
| 27 | G | 18 | M2 | Neutral | 8 | Mitoxantrone | No CR |
| 28 | T | 55 | M1 | Neutral | — | HOVON30 | No CR** |
| 29 | T | 49 | M2 | Neutral | 6 | NT | |
| 30 | G | 67 | M2 | Neutral | 5 | HOVON30 | No CR |
CR indicates complete remission after 1 or 2 courses of reinduction chemotherapy; No CR, refractory disease at time of relapse, No CR** indicates never CR after diagnosis; NT, not treated for relapse. For karyotypes, unfavorable indicates t(9;22), 11q23 with MLL rearrangements, complex karyotype, 5q-; favorable indicates inv(16), t(15;17) and t(8;21); and neutral indicates normal and other karyotypes.